Meanwhile other I/O players gaining momentum:
'Libtayo first line treatment in advanced NSCLCC prolongs survival - early phase 3 data".
In addition to improving survival, Libtayo increased the proportion of people who responded to treatment, and lowered their risk of death or disease progression, compared with chemo.
The study’s findings were recently presented as a late-breaking abstract at ESMO, titled “EMPOWER-Lung 1"
Developer - Regeneron in collaboration with Sanofi. 710 participants. Libtayo increased patients survival from 14.3 months (standard of care- chemo) to 22.1 months (Libtayo - mono).
Noting:-
“In new analyses presented at ESMO, Libtayo reduced the risk of death by 43% in patients whose cancer had confirmed PD-L1 expression of 50% or greater.
Perhaps Efti could further improve 'allcomer' PD-L1 expression as it currently is doing with Pembro?
- Forums
- ASX - By Stock
- IMM
- LAG525 Solid and Hematologic Malignancies trial completed
LAG525 Solid and Hematologic Malignancies trial completed, page-11
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
32.0¢ |
Change
0.015(4.92%) |
Mkt cap ! $464.8M |
Open | High | Low | Value | Volume |
30.0¢ | 32.5¢ | 30.0¢ | $1.168M | 3.702M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 148547 | 32.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
32.5¢ | 51809 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 148547 | 0.320 |
3 | 107807 | 0.315 |
2 | 38192 | 0.310 |
2 | 58192 | 0.305 |
10 | 490669 | 0.300 |
Price($) | Vol. | No. |
---|---|---|
0.325 | 44309 | 1 |
0.330 | 179497 | 6 |
0.335 | 82304 | 5 |
0.340 | 49303 | 3 |
0.345 | 27527 | 3 |
Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
Previous Video
Next Video
SPONSORED BY The Market Online